vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与RCM TECHNOLOGIES, INC.（RCMT）财务数据对比。点击上方公司名可切换其他公司
RCM TECHNOLOGIES, INC.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.1倍（$86.5M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 12.4%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 9.6%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
埃克塞拉科技是一家美国业务流程自动化企业，由SourceHOV、Novitex Holdings与Quinpario Acquisition Corp. 2合并组建，专注为各行业客户提供自动化业务解决方案，助力企业优化运营流程、提升运转效率。
PBYI vs RCMT — 直观对比
营收规模更大
RCMT
是对方的1.1倍
$75.5M
营收增速更快
PBYI
高出15.3%
12.4%
两年增速更快
PBYI
近两年复合增速
9.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $86.5M |
| 净利润 | — | $6.1M |
| 毛利率 | 69.3% | 28.1% |
| 营业利润率 | 22.7% | 9.2% |
| 净利率 | — | 7.1% |
| 营收同比 | 27.7% | 12.4% |
| 净利润同比 | — | 112.9% |
| 每股收益（稀释后） | $0.26 | $0.80 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIRCMT
| Q1 26 | — | $86.5M | ||
| Q4 25 | $75.5M | — | ||
| Q3 25 | $54.5M | $70.3M | ||
| Q2 25 | $52.4M | $78.2M | ||
| Q1 25 | $46.0M | $84.5M | ||
| Q4 24 | $59.1M | $76.9M | ||
| Q3 24 | $80.5M | $60.4M | ||
| Q2 24 | $47.1M | $69.2M |
净利润PBYIRCMT
| Q1 26 | — | $6.1M | ||
| Q4 25 | — | — | ||
| Q3 25 | $8.8M | $2.3M | ||
| Q2 25 | $5.9M | $3.8M | ||
| Q1 25 | $3.0M | $4.2M | ||
| Q4 24 | — | $2.9M | ||
| Q3 24 | $20.3M | $2.7M | ||
| Q2 24 | $-4.5M | $3.8M |
毛利率PBYIRCMT
| Q1 26 | — | 28.1% | ||
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | 27.6% | ||
| Q2 25 | 76.5% | 28.5% | ||
| Q1 25 | 77.1% | 26.0% | ||
| Q4 24 | 76.4% | 28.0% | ||
| Q3 24 | 63.9% | 29.6% | ||
| Q2 24 | 77.4% | 28.9% |
营业利润率PBYIRCMT
| Q1 26 | — | 9.2% | ||
| Q4 25 | 22.7% | — | ||
| Q3 25 | 17.6% | 5.6% | ||
| Q2 25 | 12.7% | 8.4% | ||
| Q1 25 | 8.7% | 7.8% | ||
| Q4 24 | 22.6% | 8.2% | ||
| Q3 24 | 27.4% | 7.3% | ||
| Q2 24 | -4.6% | 8.4% |
净利率PBYIRCMT
| Q1 26 | — | 7.1% | ||
| Q4 25 | — | — | ||
| Q3 25 | 16.2% | 3.2% | ||
| Q2 25 | 11.2% | 4.8% | ||
| Q1 25 | 6.5% | 5.0% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | 25.2% | 4.5% | ||
| Q2 24 | -9.6% | 5.4% |
每股收益（稀释后）PBYIRCMT
| Q1 26 | — | $0.80 | ||
| Q4 25 | $0.26 | — | ||
| Q3 25 | $0.17 | $0.30 | ||
| Q2 25 | $0.12 | $0.50 | ||
| Q1 25 | $0.06 | $0.54 | ||
| Q4 24 | $0.40 | $0.38 | ||
| Q3 24 | $0.41 | $0.35 | ||
| Q2 24 | $-0.09 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $2.9M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $46.0M |
| 总资产 | $216.3M | $134.4M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYIRCMT
| Q1 26 | — | $2.9M | ||
| Q4 25 | $97.5M | — | ||
| Q3 25 | $94.4M | $1.3M | ||
| Q2 25 | $96.0M | $5.5M | ||
| Q1 25 | $93.2M | $5.2M | ||
| Q4 24 | $101.0M | $4.7M | ||
| Q3 24 | $96.7M | $3.2M | ||
| Q2 24 | $96.8M | $3.5M |
总债务PBYIRCMT
| Q1 26 | — | — | ||
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — |
股东权益PBYIRCMT
| Q1 26 | — | $46.0M | ||
| Q4 25 | $130.3M | — | ||
| Q3 25 | $115.3M | $41.4M | ||
| Q2 25 | $104.7M | $37.8M | ||
| Q1 25 | $97.1M | $34.6M | ||
| Q4 24 | $92.1M | $33.5M | ||
| Q3 24 | $71.1M | $30.0M | ||
| Q2 24 | $48.5M | $28.5M |
总资产PBYIRCMT
| Q1 26 | — | $134.4M | ||
| Q4 25 | $216.3M | — | ||
| Q3 25 | $202.9M | $129.8M | ||
| Q2 25 | $194.9M | $135.6M | ||
| Q1 25 | $196.2M | $121.0M | ||
| Q4 24 | $213.3M | $132.1M | ||
| Q3 24 | $220.7M | $125.5M | ||
| Q2 24 | $205.0M | $118.3M |
负债/权益比PBYIRCMT
| Q1 26 | — | — | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $19.0M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | — |
| 自由现金流率自由现金流/营收 | 19.1% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 3.11× |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYIRCMT
| Q1 26 | — | $19.0M | ||
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $-1.3M | ||
| Q2 25 | $14.1M | $-7.9M | ||
| Q1 25 | $3.6M | $16.7M | ||
| Q4 24 | $15.6M | $-1.6M | ||
| Q3 24 | $11.0M | $-4.3M | ||
| Q2 24 | $1.0M | $5.7M |
自由现金流PBYIRCMT
| Q1 26 | — | — | ||
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $-1.8M | ||
| Q2 25 | $14.1M | $-8.4M | ||
| Q1 25 | $3.6M | $16.2M | ||
| Q4 24 | $15.6M | $-2.6M | ||
| Q3 24 | $11.0M | $-4.9M | ||
| Q2 24 | $1.0M | $5.3M |
自由现金流率PBYIRCMT
| Q1 26 | — | — | ||
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | -2.5% | ||
| Q2 25 | 26.8% | -10.7% | ||
| Q1 25 | 7.7% | 19.2% | ||
| Q4 24 | 26.4% | -3.4% | ||
| Q3 24 | 13.7% | -8.1% | ||
| Q2 24 | 2.1% | 7.7% |
资本支出强度PBYIRCMT
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.1% | 0.5% | ||
| Q4 24 | 0.0% | 1.3% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 0.0% | 0.6% |
现金转化率PBYIRCMT
| Q1 26 | — | 3.11× | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | -0.56× | ||
| Q2 25 | 2.41× | -2.08× | ||
| Q1 25 | 1.21× | 3.98× | ||
| Q4 24 | — | -0.57× | ||
| Q3 24 | 0.54× | -1.58× | ||
| Q2 24 | — | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
